Addison C., Jenkins J. R., and Sturzbecher H. W. (1990). The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene 5: 423-426.
Agarwal M. L., Agarwal A., Taylor W. R., and Stark G. R. (1995). p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92: 8493-8497.
Akashi M., Osawa Y., Koeffler H. P., and Hachiya M. (1999). p21WAF1 expression by an activator of protein kinase C is regulated mainly at the posttranscriptional level in cells lacking p53: important role of RNA stabilization. Biochem. J. 337: 607-616.
Akslen L. A., Moenstad S. E., Larsen B., Straume I., and Igreid D. (1998). Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int. J. Cancer 79: 91-95.
Albino A. P., Vidal M. J., McNutt N. S., Shea C. R., Prieto V. G., Nanus D. M., Palmer J. M., and Hayward N. K. (1994). Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4: 35-45.
Andrews N.C., and Faller D.V. (1991). A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 19: 249.
Aloni-Grinstein R., Zanbar I., Alboum I., Goldfinger N., and Rotter V. (1993). Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 8: 3297-3305.
Araki R., Fujimori A., Hamatani K., Mita K., Saito T., Mori M., Fukumura R., Morimyo M., Muto M., Itoh M., Tatsumi K., and Abe M. (1997). Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. Proc. Natl. Acad. Sci. USA 94: 2438-2443.
Armstrong J. F., Kaufman M. H., Harrison D. J., and Clarke A. R. (1995). High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5: 931-936.
Ashcroft M., Kubbutat M. H., and Vousden K. H. (1999). Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19: 1751-1758.
Bae I., Smith M. L., Sheikh M. S., Zhan Q., Scudiero D. A., Friend S. H., O´Connor P. M., and Fornace A. J. Jr. (1996). An abnormality in the p53 pathway following gamma-radiation in many wild-type p53 human melanoma cell lines. Cancer Res. 56: 840-847.
Bai F., Matsui T., Ohtani-Fujita N., Matsukawa Y., Ding Y., and Sakai T. (1998). Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G1 phase growth arrest in A549 lung adenocarcinoma cells. FEBS Lett. 437: 61-64.
Bakalkin G., Yakovleva T., Selivanova G., Magnusson K. P., Szekely L., Kiseleva E., Klein G., Terenius L., and Wiman K. G. (1994). p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA 91: 413-417.
Baker S. J., Fearon E. R., Nigro J. M., Hamilton S. R., Preisinger A. C., Jessup J. M., vanTuinen P., Ledbetter D. H., Barker D. F., and Nakamura Y. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221.
Baker S. J., Markowitz S., Fearon E. R., Willson J. K., and Vogelstein B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
Banin S., Moyal L., Shieh S., Taya Y., Anderson C. W., Chessa L., Smorondinsky N. I., Prives C., Reiss Y., Shiloh Y., and Ziv Y. (1998). Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
Barak Y., Gottlieb E., Juven-Gershon T., and Oren M. (1994). Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8: 1739-1749.
Bargonetti J., Manfredi J. J., Chen X., Marshak D. R., and Prives C. (1993). A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7: 2565-2574.
Bartek J., Bartkova J., and Lukas J. (1996). The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 8: 805-814.
Bartek J., Bartkova J., and Lukas J. (1997). The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 237: 1-6.
Bates S., Phillips A. C., Clark P. A., Stott F., Peters G., Ludwig R. L., and Vousden K. H. (1998). p14ARF links the tumour suppressors RB and p53. Nature 395: 124-125.
Bellamy C. O., Clarke A. R., Wyllie A. H., and Harrison D. J. (1997). p53 deficiency in liver reduces local control of survival and proliferation, but does not affect apoptosis after DNA damage. FASEB J. 11: 591-599.
Benedict W. F., Lerner S. P., Zhou J., Shen X., Tokunaga H., and Czerniak B. (1999). Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18: 1197-1203.
Beroud C., and Soussi T. (1998). p53 gene mutation: software and database. Nucleic Acids Res. 26: 202-207.
Berry D. E., Lu Y., Schmidt B., Fallon P. G., O Connell C., Hu S.-X., Xu H.-J., and Blanck G. (1996). Retinoblastoma protein inhibits IFN-gamma induced apoptosis. Oncogene 12: 1809-1819.
Biggs J. R., Kudlow J. E., and Kraft A. S. (1996). The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J. Biol. Chem. 271: 901-906.
Birch J. M., Hartley A. L., Tricker K. J., Prosser J., Condie A., Kelsey A. M., Harris M., Jones P. H., Binchy A., and Crowther D. (1994). Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 54: 1298-1304.
Birch J. M., Blair V., Kelsey A. M., Evans D. G., Harris M., Tricker K. J., and Varley J. M. (1998). Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17: 1061-1068.
Bischoff J. R., Friedman P. N., Marshak D. R., Prives C., and Beach D. (1990). Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc. Natl. Acad. Sci. USA 87: 4766-4770.
Bissonnette N., and Hunting D. J. (1998). p21-induced growth arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16: 3461-3469.
Blattner C., Tobiasch E., Litfen M., Rahmsdorf H. J., and Herrlich P. (1999). DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18: 1723-1732.
Blaydes J. P., Gire V., Rowson J. M., and Wynford-Thomas D. (1997). Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on autoregulation by mdm-2. Oncogene 14: 1859-1868.
Bookstein R., Lee E. Y., Peccei A., and Lee W. H. (1989). Human retinoblastoma gene; long-range mapping and analysis of its deletion in a breast cancer cell line. Mol. Cell. Biol. 9: 1628-1634.
Bootsma D., and Hoeijmakres J. H. (1993). DNA repair. Engagement with transcription. Nature 363: 114-115.
Bootsma D. (1993). The genetic defect in DNA repair deficiency syndromes. European Journal of Cancer 29A: 1482-1488.
Bourre F., Renault G., and Sarasin A. (1987). Sequence effect on alkali-sensitive sites in UV-irradiated SV40 DNA. Nucleic Acids Res. 15: 8861-8875.
Brain R., and Jenkins J. R. (1994). Human p53 directs DNA strans reassociation and is photolabelled by 8-azido ATP. Oncogene 9: 1775-1780.
Brown J. P., Wei W., and Sedivy J. M. (1997). Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal human fibroblasts. Science 277: 831-834.
Brugarolas J., Chandrasekaran C., Gordon J. I., Beach D., Jacks T., and Hannon G. J. (1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557.
Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Fha B., Seizinger B. R., and Kley N. (1995). Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649.
Butz K., Geisen C., Ullmann A., Zentgraf H., and Hoppe-Seyler F. (1998). Uncoupling of p21WAF1/CIP1/SDI1 mRNA and protein expression upon genetoxic stress. Oncogene 17: 781-787.
Caelles C., Helmberg A., and Karin M. (1994). p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223.
Cahilly-Snyder L., Yang-Feng T., Francke U., and George D. L. (1987). Molecular analysis and choromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell. Mol. Genet. 13: 235-244.
Canman C. E., Lim D. S., Cimprich K. A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M. B., and Siliano J. D. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679.
Castellano M., Pollock P. M., Walters M. K., Sparrow L. E., Down L. M., Gabrielli B. G., Parsons P. G., and Hayward N. K. (1997). CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 57: 4868-4875.
Cavanaugh A. H., Hempel W. M., Taylor L. J., Rogalsky trong L. C., and White R. L. (1988). Expression of recessive alleles by choromosomal mechanisms in retinoblastoma. Nature 305: 779-784.
Cavanaugh A.H., Hempel W.M., Taylor L.J., Rogalsky V., Todorov G., and Rothblum L. I. (1995). Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 374: 177-180.
Cavenee W. K., Dryja T. P., Phillips R. A., benedict W. F., Godbout R., Gallie B. L., Murphree a. L., S1739-1749.
Cayrol C., Knibiehler M., and Ducommun B. (1998). p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16: 311-320.
Chellappan S. P., Hiebert S., Mudryj M., Horowitz J. M., and Nevis J. R. (1991). The E2F transcription factor is the cellular target for the RB protein. Cell 65: 1053-1061.
Chen C., and Okayama H. (1987). High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7: 2745-2752.
Chen J., Jackson P. K., Kirschner M. W., and Dutta A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374: 386-388.
Chin Y. E., Kitagawa M., Su W.-C. S., You Z.-H., Iwamoto Y., and Fu X.-Y. (1996). Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science 272: 719-722.
Cho Y., Gorina S., Jeffrey P. D., and Pavletich N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
Chowdary D. R., Dermody J. J., Jha K. K., and Ozer H. L. (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Molec. Cell Biol. 14: 1997-2003.
Clarke A., Maandag E., van Roon M., van der Lugt N., van der Valk M., Hooper M., Berns A., and te Riele H. (1992). Requirement for a functional Rb-1 gene in murine development. Nature 359: 328-330.
Clarke A. R., Purdie C. A. H. D.J., Morris R. G., Bird C. C., Hooper M. L., and Wyllie A. H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852.
Clore G. M., Ernst J., Clubb R., Omichinski J. G., Kennedy W. M., Sakaguchi K., Appella E., and Gronenborn A. M. (1995a). Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. 2: 321-333.
Clore G. M., Omichinski J. G., Skaguchi K., Zambrano N., Sakamoto H., Appella E., and Gronenborn A. M. (1995b). Interhelical angles in the solution structure of the oligomerization domain of p53: correction. Science 267: 1515-1516.
Cordon-Cardo C., Latres E., Drobnjak M., Oliva M. R., Pollack D., Woodruff J. M., Marechal V., Chen J., Brennan M. F., and Levine A. J. (1994). Molecular abnormalities of mdm2 and p53 genes in soft tissue sarcomas. Cancer Res. 54: 794-799.
Cross S. M., Sanchez C. A., Morgan C. A., Schimke M. K., Ramel S., Idzerda R. L., Raskind W. H., and Reind B. J. (1995). A p53-dependent mouse spindle checkpoint. Science 267: 1353-1356.
Cziepluch C., Wenzel A., Schurmann J., and Schwab M. (1993). Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1. Oncogene 8: 2833-2838.
Dameron K. M., Volpert O. V., Tainsky M. A., and Bouck N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584.
Danielsen T., Hvidsten M., Stokke T., Solberg K., and Rofstad E. K. (1998). Hypoxia induces p53 accumulation in the S-phase and accumulation of hypophosphorylated retinoblastoma protein in all cell cycle phases of human melanoma cells. Br. J. Cancer 78: 1547-1558.
Datto M. B., Yu Y., and Wang X.-F. (1995). Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 270: 28623-28628.
Debbas M., and White E. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7: 546-554.
DeCaprio J. A., Ludlow J. W., Figge J., Shew J. Y., Huang C. M., Lee W. H., Marsilio E., Paucha E., and Livingston D. M. (1988). SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54: 275-283.
DeFrank J., Tang S. W., and Powell S. N. (1996). p53-null cells are more sensitive to ultraviolet light only in the presence of caffeine. Cancer Res. 56: 5365-5368.
DeGregori J., Leone G., Miron A., Jakoi L., and Nevins J. R. (1997). Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA 94: 7245-7250.
Del Sal G., Ruaro E. M., Utrera R., Cole C. N., Levine A. J., and Schneider C. (1995). Gas1-induced growth suppression requires a transactivation-independent p53 function. Mol. Cell. Biol. 15: 152-160.
Demers G. W., Foster S. A., Halbert C. L., and Galloway D. A. (1994). Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA 91: 4381-4386.
Deng C., Zhang P., Harper J. W., Elledge S. J., and Leder P. (1995). Mice lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
DerKinderen D. J., Koten J. W., Nagelkerke N. J. D., Tan K. E., Beemer F. A., and Den Otter W. (1988). Non-ocular cancer in patients with herediatry retinoblastoma and their relatives. Int. J. Cancer 41: 499-504.
Di Leonardo A., Linke S. P., Clarkin K., and Wahl G. M. (1994). DNA damage triggers a prolonged p53-dependent G1 growth arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8: 2540-2551.
Donehower L. A., Harvey B. L., Slagle B. L., McArthur M. J., Montgomery C. A., Butel J. S., and Bradley A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., and Reed S. I. (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023.
Dulic V., Stein G. H., Far D. F., and Reed S. I. (1998). Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol. Cell. Biol. 18: 546-557.
Dumaz N., Duthu A., Ehrhart J. C., Drougard C., Appella E., Anderson C. W., May P., Sarasin A., and Daya-Grosjean L. (1997). Prolonged p53 protein accumulation in trichothiodystrophy fibroblasts dependent on unrepaired pyrimidine dimers on the transcribed strands of cellular genes. Mol. Carcinog. 20: 340-347.
Dumaz N., Drougard C., Quilliet X., Mezzina M., Sarasin A., and Daya-Grosjean L. (1998). Recovery of the normal p53 response after UV treatment in DNA repair-deficient fibroblasts by retroviral-mediated correction with the XPD gene. Carcinogenesis 19: 1701-1704.
Dutta A., Ruppert S. M., Aster J. C., and Winchester E. (1993). Inhibition of DNA replication factor RPA by p53. Nature 365: 79-82.
Duttaroy A., Qian J. F., Smith J. S., and Wang E. (1997). Up-regulated p21(CIP1) expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis. J. Cell Biochem. 64: 434-446.
Dyson N., Howley P. M., Munger K., and Harlow E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934-936.
Dyson N. (1998). The regulation of E2F by pRB-family members. Genes Dev. 12: 2245-2262.
El-Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., and Vogelstein B. (1992). Definition of a consensus binding site for p53. Nature Genet. 1: 45-49.
El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., and Vogelstein B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
El-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y., Wiman K. G., Mercer W. E., Kastan M. B., Kohn K. W., Elledge S. J., Kinzler K. W., and Vogelstein B. (1994). WAF1/CIP1 in induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54: 1169-1174.
El-Deiry W. S., Tokino T., Waldman T., Oliner J. D., Velculescu V. E., Burrell M. ã., Hill D. E., Hearly E., Rees J. L., Hamilton S. R., Kinzler K. W., and Vogelstein B. (1995). Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissue. Cancer Res. 55: 2910-2919.
Essner R., Kuo C. T., Wang H., Wen D. R., Turner R. R., Nguyen T., and Hoon D. S. (1998). Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 82: 309-316.
Fakharzadeh S. S., Trusko S. P., and George D. L. (1991). Tumorigenic potential associated with enhanced expession of a gene that is amplified in a mouse tumor cell line. EMBO 10: 1565-1569.
Fang X., Jin X., Xu H. J., Liu L., Peng H. Q., Hogg D., Roth J. A., Yu Y., Xu F., Bast R. C. j., and Mills G. B. (1998). Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16: 1-8.
Finlay C. A., Hinds P. W., and Levine A. J. (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093.
FitzGerald M. G., Harkin D. P., Silva-Arrieta S., MacDonald D. J., Lucchina L. C., Unsal H., O´Neill E., Koh J., Finkelstein D. M., and Isselbacher K. J. (1996). Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA 93: 8541-8545.
Florenes V. A., Maelandsmo G. M., Forus A., Andreassen A., Myklebost O., and Fodstad O. (1994a). MDM2 gene amplification and transcript level in hiuman sarcomas: relatioship to TP53 gene status. The Journal of National Cancer Institute 86: 1297-1302.
Florenes V. A., Iyjord T., Holm R., Skrede M., Boerresen A. L., Nesland J. M., and Foestad I. (1994b). TP53 allele loss, mutations and expression in malignant melanoma. Br. J. Cancer 69: 253-259.
Florenes V. A., Holm R., and Foested I. (1995). Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome. Melanoma Res. 5: 183-187.
Flores-Rozas H., Kelman Z., Dean F. B., Pan Z. Q., Harper J. W., Elledge S. J., O'Donnell M., and Hurwitz J. (1994). Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA 91: 8655-8659.
Ford J. M., and Hanawalt P. C. (1995). Li-Fraumeni syndrome fibroblasts honozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcripion-coupled repair and enhanced UV resistance. Proc. Natl. Acad. Sci. USA 92: 8876-8880.
Ford J. M., and Hanawalt P. C. (1997). Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem. 272: 28073-28080.
Fornace A. J. Jr., Alamo, I., and Hollander M.C. (1988). DNA damage-inducible transcripts in mammalian cells. Proc. Natl. Acad. Sci. USA 85: 8800-8804.
Fornace A. J. Jr., Nebert D. W., Hollander M. C., Luethy J. D., Papathanasiou M., Fargoli J., and Holbrook N. J. (1989). Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell. Biol. 9: 4196-4203.
Friend S. H., Bernards R., Rogelj S., Weinberg R. A., Rapaprt J. M., Albert D. M., and Dryja T. P. (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323: 643-646.
Fuchs E. J., McKenna K. A., and Bedi A. (1997). p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. Cancer Res. 57: 2550-2554.
Gartel A. L., and Tyner A. L. (1999). Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp. Cell Res. 246: 280-289.
Goga A., Liu X., Hambuch T. M., Senechal K., Major E., Berk A. J., Witte O., and Sawyers C. L. (1995). p53-dependent growth suppression by the c-Abl nuclear tyrosine kinase. Oncogene 11: 791-799.
Gorman C.M., Moffat L.F., and Howard B.H. (1982). Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2: 1044-1051.
Gorospe M., Cirielli C., Wang X., Seth P., Capogrossi M., and Holbrook N. (1997). p21 (WAF1/CIP1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14: 929-935.
Gorospe M., Wang X., and Holbrook N. J. (1998). p53-dependent elevation of p21Waf1 expression by UV light is mediated through mRNA stabilization and involves a vanadate-sensitive regulatory system. Mol. Cell. Biol. 18: 1400-1407.
Graeber T. G., Peterson J. F., Tsai M., Monica K., Fornace A. J. J., and Giaccia A. J. (1994). Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14: 6264-6277.
Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W., and Giaccia A. J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379: 88-91.
Grana X., and Reddy E.P. (1995). Cell cycle control in mammalian cells. Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors. Oncogene 11: 211-219.
Grossman S. R., Perez M., Kung A. L., Joseph M., Mansur C., Xiao Z. X., Kumar S., Howley P. M., and Livingston D. M. (1998). p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Molecular Cell 2: 405-415.
Gruis N. A., van der Velden S. L.A., Prins D. E., Weaver-Feldhouse J., Kamb A., Bergman W., and Frants R. (1995). Homozygotes for CDKN2(p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10: 351-353.
Gu W., and Roeder R. G. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
Gudas J., Nguyen H., LI T., Hill D., and Cowan K. H. (1995). Effects of cell cycle, wild type p53 and DNA damage on p21 CIP1/Waf1 expression in human breast epithelial cells. Oncogene 11: 253-261.
Gurley K. E., and Kemp C. J. (1996). p53 induction, cell cycle checkpoints, and apoptosis in DNAPK-deficient scid mice. Carcinogenesis 17: 2537-2542.
Haas-Kogan D. A., Kogan S. C., Levi D., Dazin P., TAng A., Fung Y.-K. T., and Israel M. A. (1995). Inhibition of apoptosis by the retinoblastoma gene product. EMBO 14: 461-472.
Hainaut P., and Milner J. (1993). Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53: 4469-4473.
Halazonetis T. D., Davis L. J., and Kandil A. N. (1993). Wild-type p53 adopts a "mutant"-like conformation when bound to DNA. EMBO 12: 1021-1028.
Haldar S., Negrini M., Monne M., Sabbioni S., and Croce C. M. (1994). Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54: 2095-2097.
Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., and Lassar A. B. (1995). Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267: 1018-1021.
Hall P. A., Kearsey J. M., Coates P. J., Norman D. G., Warbrick E., and Cox L. S. (1995). Characterization of the interaction between PCNA and Gadd45. Oncogene 10: 2427-2433.
Hamel P. A., Gill R. M., Philips R. A., and Gallie B. L. (1992). Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of RB1 gene. Mol. Cell. Biol. 12: 3431-3438.
Harbour J. W., Lai S. L., Whang-Peng J., Gazdar A. F., Minna J. D., and Kaye F. J. (1988). Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353-357.
Harper J. W., Adami G. R., Wei N., Keyomarsi K., and Elledge S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
Harper J. W., Elledge S. J., Keyomarsi K., Dynlacht B., Tsai L., Zhang P., Dobtolowski S., Bai C., Connell-Crowley L., Swindell E., Fox M. P., and Wei N. (1995). Inhibition of cyclin dependent kinases by p21. Mol. Biol. Cell 6: 387-400.
Harrington E. A., Bruce J. L., Harlow E., and Dyson N. (1998). pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc. Natl. Acad. Sci. USA 95: 11945-11950.
Hartmann A., Blaszyk H., Cunningham J. S., McGovern R. M., Schroeder J. S., Helander S. D., Pittelkow M. R., Sommer S. S., and Kovach J. S. (1996). Overexpression and mutations in metastatic malignant melanomas. Int. J. Cancer 67: 253-259.
Harvey M., McArthur M. J., Montgomery C. A. Jr., Bradley A., and Donehower L. A. (1993a). Genetic backround alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7: 938-943.
Harvey M., McArthur M. J., Montgomery C. A. Jr., Butel J. S., Bradley A., and Donehower L. A. (1993b). Spontaneous and carsinogen-induced tumorigenesis in p53-deficient mice. Nature Genet. 5: 225-229.
Harvey M., Sands A. T., Weiss R. S., Hegi M. E., Wiseman R. W., Pantazis P., Giovanella B. C., Tainsky M. A., Bradley A., and Donehower L. A. (1993c). In vitro growth characteristics of embryo fibroblasts from p53-deficient mice. Oncogene 8: 2457-2467.
Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., and Donehower L. A. (1995). A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet. 9: 305-311.
Haupt Y., Rowan S., and Oren M. (1995). p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10: 1563-1571.
Haupt Y., Barak Y., and Oren M. (1996). Cell type specific inhibition of p53-mediated apoptosis by mdm2. EMBO 15: 1596-1606.
Haupt Y., Maya R., Kazaz A., and Oren M. (1997). Mdm2 promotes rapid degradation of p53. Nature 387: 296-299.
Healy E., Belgaid C., Takata M., Harrison D., Zhu N. W., Burd D. A., Rigby H. S., Matthews J. N., and Rees J. L. (1998). Prognostic significance of allelic losses in primary melanoma. Oncogene 16: 2213-2218.
Herrera R. E., Sah V. P., Williams B. O., Mäkelä T. P., Weinberg R. A., and Jacks T. (1996). Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol. Cell. Biol. 16: 2402-2407.
Herrmann C. P., Kraiss S., and Montenarh M. (1991). Association of casein kinase II with immunopurified p53. Oncogene 6: 877-884.
Hinds P. W., Mittnacht S., Dulic V., Arnold A., Reed S. I., and Weinberg R. A. (1992). Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70: 993-1006.
Holland E. A., Beaton S. C., Becker T. M., Grulet O. M. C., Peters B. A., Rizos H., Kefford R. F., and Mann G. J. (1995). Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11: 2289-2294.
Hollander M. C., Alamo I., Jackman J., Wang M. G., McBride O. W., and Fornace A. J. Jr. (1993). Analysis of the mammalian gadd45 gene and its response to DNA damage. J. Biol. Chem. 268: 24385-24393.
Hollstein M., Sidransky D., Vogelstein B., and Harris C. C. (1991). p53 mutations in human cancers. Science 253: 49-53.
Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sorlie T., Hovig E., Smith-Sorensen B., Montesano R., and Harris C. C. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22: 3551-3555.
Honda R., Tanaka H., and Yasuda H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27.
Honda R., and Yasuda H. (1999). Association of p19ARF with the Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO 18: 22-27.
Horikoshi N., Usheva A., Chen J., Levine A. J., Weinmann R., and Shenk T. (1995). Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol. 15: 227-234.
Horowitz J. M., Park S. H., Bogenmann E., Cheng J. C., Yandell D. W., Kaye F. J., Minna J. D., Dryja T. P., and Weinberg R. A. (1990). Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl. Acad. Sci. USA 87: 2775-2779.
Howes K. A., Ransom N., Papermaster D. S., Lasudry J. G., Albert D. M., and Windle J. J. (1994). Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 8: 1300-1310.
Hsiao M., Low J., Dorn E., Ku D., Pettengale P., Yeargin J., and Haas M. (1994). Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145: 702-714.
Hu N., Gutsman A., Herbert d. C., Bradley A., Lee W. H., and Lee E. Y. (1994). Heteroxygous Rb-1 delta 20/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9: 1021-1027.
Hupp T. R., Meek D. W., Midgley C., and Lane D. P. (1992). Regulation of the specific DNA binding function of p53. Cell 71: 875-886.
Hupp T. R., Meek D. W., Midgley C. A., and Lane D. P. (1993). Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21: 3167-3174.
Hupp T. R., Sparks A., and Lane D. P. (1995). Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83: 237-249.
Hussussian C. J., Struewing J. P., Goldstein A. M., Higgins P. A. T., Ally D. S., Sheahan M. D., Clark W. H. Jr., Tucker M. A., and Dracopoli N. C. (1994). Germline p16 mutations in familial melanoma. Nature Genet. 8: 15-21.
Ishizaki K., Ejima Y., Matsunaga T., Hara R., Sakamoto A., Ikenaga Y., and Aizawa S. (1994). Increased UV-induced SCEs but normal repair of DNA damage in p53-deficient mouse cells. Int. J. Cancer 58: 254-257.
Iwabuchi K., Li B., Massa H. F., Trask B. J., Date T., and Fields S. (1998). The Journal Biological Chemistry. The Journal Biological Chemistry 273: 26061-26068.
Jacks T., Fazeli A., Schmitt E., Bronson R., Goodell M., and Weinberg R. (1992). Effects of Rb mutation in the mouse. Nature 359: 295-300.
Jayamaran L., and Prives C. (1995). Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029.
Jiang H., Lin J., Su Z.-Z., Collart F. R., Huberman E., and Fisher P. B. (1994). Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CP1, expression in the absence of p53. Oncogene 9: 3397-3406.
Johnson D. G., Schwarz J. K., Cress W. D., and Nevins J. R. (1993). Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365: 349-352.
Johnson D. G., Cress W. D., Jakoi L., and Nevins J. R. (1994). Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA 91: 12823-12827.
Jones S. N., Roc A. E., Donehower L. A., and Bradley A. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
Jost C.A., Marin M.C., and Kaelin W.G. Jr. (1997). p73 is a human p53-related protein that can induce apoptosis. Nature 389: 191-194.
Juven T., Barak Y., Zauberman A., George D. L., and Oren M. (1993). Wild type p53 can mediate sequence-specific transactivation of an internal promoter within mdm2 gene. Oncogene 8: 3411-3416.
Kaghad M., Bonnet H., yang A., Creancier L., Biscan J.C., valent A., Minty A., Chalon P., Lelias J.M., dumont X., Ferrara P., McKeon F., and Caput D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastomas and other human cancers. Cell 90: 809-819.
Kamb A. (1995). Cell-cycle regulators and cancer. Trends Gen. 11: 136-140.
Kamijo T., Zindy F., Roussel M. F., Quelle D. E., Downing J. R., Ashmun R. A., Grosveld G., and Sherr C. J. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659.
Kamijo T., Weber J. D., Zambetti G., Zindy F., Roussel M. F., and Sherr C. J. (1998). Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95: 8292-8297.
Kapoor M., and Lozano G. (1998). Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. USA 95: 2834-2837.
Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., and Craig R. W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311.
Kastan M. B., Zhan Q., El-Deiry W. S., Carrier F., Jacks T., Walsh W. V., Plunkett B. S., Vogelstein B., and Fornace A. J. J. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
Kaufmann W. K. (1989). Pathways of human cell post-replication repair. Carcinogenesis 10: 1-11.
Kearsey J. M., Coates P. J., Prescott A. R., Warbrick E., and Hall P. A. (1995). Gadd45 is a nuclear cell cycle regulated protein which interacts with p21Cip1. Oncogene 11: 1675-1683.
Kelley L. L., Green W. F., Hicks G. G., Bondurant M. C., Koury M. J., and Ruley H. E. (1994). Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol. Cell. Biol. 14: 4183-4192.
Kelman Z., Prokocimer M., Peller S., Kahn Y., Rechavi G., Manor Y., Cohen A., and Rotter V. (1989). Rearrangements in the p53 gene in Philadelphia chromosome positive chronic meylogenous leukemia. Blood 74: 2318-2324.
Kelman Z. (1997). PCNA: Structure, functions and interactions. Oncogene 14: 629-640.
Kern S.E., Pietenpol J.A., Thiagalingam S., Seymor A., Kinzler K., and Vogelstein B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827-830.
Khanna K. K., and Lavin M. F. (1993). Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8: 3307-3312.
Kieser A., Weich H. A., Brandner G., Marme D., and Kolch W. (1994). Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963-969.
Kivinen L., Tsubari M., Pitkänen K., and Laiho M. (1999). Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites. Oncogene in press.
Knudsen E. S., and Wang J. Y. J. (1996). Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. 271: 8313-8320.
Knudson C. M., Tung K. S., Tourtellotte W. G., Brown G. A., and Korsmeyer S. J. (1995). Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270: 96-99.
Konze-Thomas B., Hazard R. M., Maher V. M., and McCormick J. J. (1982). Extent of excision repair before DNA synthesis determines the mutagenic but not the lethal effect of UV radiation. Mutat. Res. 94: 421-434.
Korabiowska M., Betke H., Kellner S., Stachura J., and Schauer A. (1997). Differential expression of growth arrest, DNA damage genes and tumour suppressor gene p53 in naevi and malignant melanoma. Anticancer Res. 17: 3697-3700.
Kramer D. L., Vujcic S., Diegelman P., Alderfer J., Miller J. T., Black J. D., Bergeron R. J., and Porter C. W. (1999). Polyamine analogue induction of the p53-21WAF/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res. 59: 1278-1286.
Kubbutat M. H. G., and Vousden K. H. (1997). Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17: 460-468.
Kubbutat M. H. G., Jones S. N., and Vousden K. (1997). Regulation of p53 stbility by Mdm2. Nature 387: 299-303.
Kuerbitz S. J., Plunkett B. S., Walsh W. V., and Kastan M. B. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89: 7491-7495.
LaBaer J., Garrett M. D., Stevenson L. F., Slingerland J. M., Sandhu C., Chou H. S., Fattaey A., and Harlow E. (1997). New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11: 847-862.
Landers J. E., Haines D. S., Strauss J. F. 3., and George D. L. (1994). Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750.
Landers J. E., Cassel S. L., and George D. L. (1997). Translational enhancement of mdm2 oncogene expression in human tumor cells containing the stabilized wild-type p53 protein. Cancer Res. 57: 3562-3568.
Lane D. P., and Crawford L. V. (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263.
Lassam N. J., From L., and Kahn H. J. (1993). Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res. 53: 2235-2238.
Leach F. S., Tokono T., Meltzer P., Burrell M., Oliner J. D., Smith S., Hill D. E., Sidransky D., Kinzler K. W., and Vogelstein B. (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53: 2231-2234.
Lee E. Y., To H., Shew J. Y., Bookstein R., Scully P., and Lee W. H. (1988). Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241: 218-221.
Lee E. Y., Chang C. Y., Hu N., Wang Y. C., Lai C. C., Herrup K., Lee W. H., and Bradley A. (1992). Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoiesis. Nature 359: 288-294.
Lee M.-H., Williams B. H., Mulligan G., Mukai S., Bronson R. T., Dyson N., and Helin K. (1996). Targeted disruption of p107: Functional overlap between p107 and Rb. Genes Dev. 10: 1621-1632.
Lee S., Elenbaas B., Levine A., and Griffith J. (1995). p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020.
Lee W., Harvey T. S., Yin Y., Yau P., Litchfield D., and Arrowsmith C. H. (1994). Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1: 877-890.
Lehmann A. R., and Carr A. M. (1994). DNA damage, repair and the cell cycle. Trends Cell. Biol. 4: 24-26.
Leveillard T., Andera L., Bissonnette N., Schaeffer L., Bracco L., Egly J.-M., and Wasylyk B. (1996). Functional interactions between p53 and TFIIH complex are affected by tumour-associated mutations. EMBO 15: 1615-1624.
Levy N., Yonish-Rouach E., Oren M., and Kimchi A. (1993). Complementation by wild-type p53 of interleukin-6 effects on M1 cells - induction of cell cycle exit and cooperativity with c-myc suppression. Mol. Cell. Biol. 13: 7942-7952.
Li J.-M., Datto M. B., Shen X., Hu P. P.-C., Yu Y., and Wang X.-F. (1998). Sp1, but not Sp3, functions to mediate promoter activation by TGF-betaã through canonical Sp1 binding sites. Nucleic Acids Res. 26: 2449-2456.
Li R., Waga S., Hannon G., Beach D., and Stillman B. (1994). Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371: 539-542.
Li R., Hannon G. J., Beach D., and Stillman B. (1996). Subcellular distribution of p21 and PCNA in normal and repair deficient cells following DNA damage. Curr. Biol. 6: 189-199.
Li Y., Nichols M. A., Shay J. W., and Xiong Y. (1994). Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54: 6078-6082.
Lianes P., Orlow I., Zhang Z.-F., Oliva M. R., Sarkis A. S., Reuter V. E., and Cordon-Cardo C. (1994). Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst. 86: 1325-1330.
Lin J., Chen J., Elenbaas B., and Levine A. J. (1994). Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8: 1235-1246.
Linke S. P., Clarkin K. C., Di Leonardo A., Tsou A., and Wahl G. M. (1996). A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10: 934-947.
Linzer D. I. H., and Levine A. J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal fibroblasts. Cell 17: 43-52.
Liu M., and Pelling J. C. (1995). UV-B/A irradiation of mouse keratinocytes results in p53-mediated WAF1/CIP1 expression. Oncogene 10: 1955-1960.
Liu M., Lee M. H., Cohen M., Bommakanti M., and Freedman L. P. (1996). Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10: 142-153.
Lloyd A. C., Obermüller F., Staddon S., Barth C. F., McMahon M., and Land H. (1997). Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 11: 663-677.
Loignon M., Fetni R., Gordon A. J., and Drobetsky E. A. (1997). A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated skin fibroblasts. Cancer Res. 57: 3390-3394.
Lowe S. W., and Ruley H. E. (1993). Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7: 535-545.
Lowe S. W., Ruley H. E., Jacks T., and Housman D. E. (1993a). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
Lowe S. W., Schmitt E. M., Smith S. W., and Osborne B. A. J. T. (1993b). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
Lu H., and Levine A. J. (1995). Human TAF31 protein is a transcriptional activator of the p53 protein. Proc. Natl. Acad. Sci. USA 92: 5154-5158.
Lu H., Taya Y., Ikeda M., and Levine A. J. (1998). Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein. Proc. Natl. Acad. Sci. USA 95: 6399-6402.
Lu X., and Lane D. P. (1993). Differential induction of transcriptionally active p53 following UV or ionozing radiation: defects in chromosome instability syndromes? Cell 75: 765-778.
Lu X., Burbidge S. A., Griffin S., and Smith H. M. (1996). Discordance between accumulated p53 protein level and its transcriptional activity in response to u.v. radiation. Oncogene 13: 413-418.
Ludlow J. W., Shon J., Pipas J. M., Livingston D. M., and DeCaprio J. A. (1990). The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell 60: 387-396.
Lukas J., Parry D., Aagaard L., Mann D. J., Bartkova J., Strauss M., Peters G., and Bartek J. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375: 503-506.
Lundgren K., Montes de Oca Luna R., McNeill Y. B., Emerick E. P., Spencer B., Barfield C. R., Lozano G., Rosenberg M. P., and Finlay C. A. (1997). Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 11: 714-725.
Luo Y., Hurwitz J., and Massague J. (1995). Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 375: 159-161.
Lutzker S., and Levine A. J. (1996). A functionally inactive p53 protein in embryonal carcinoma cells is activated by DNA damage or cellular differentiation. Nature Med. 2: 804-810.
Mack D. H., Vartikar J., Pipas J. M., and Laimins L. A. (1993). Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283.
Macleod K. F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., and Jacks T. (1995). p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9: 935-944.
Macleod K. (1999). pRb and E2F-1 in mouse development and tumorigenesis. Curr. Opin. Genet. Dev. 9: 31-39.
Maelandsmo G. M., Holm R., Foestad O., Kerbel R. S., and Florenes V. A. (1996). Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastic lesions. Am. J. Pathol. 149: 1813-1822.
Maestro R., Gloghini A., Doglioni C., Piccinin S., Vukosavljevic T., Gasparotto D., Carbone A., and Boiocchi M. (1997). Human non-Hodgkin´s lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood 89: 2523-2528.
Maki C. G., Huibregtse J. M., and Howley P. M. (1996). In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56: 2649-2654.
Malkin D. (1993). p53 and the Li-Fraumeni syndrome. Cancer Genet. Cytogenet. 66: 83-92.
Maltzman W., and Czyzyk L. (1984). UV irradiation stimulate levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694.
Mao L., Merlo A., bedi G., Shapiro G. I., Edwards C. D., Rollin B. J., and Sidransky D. (1995). A novel p16/INK4a transcript. Cancer Res. 55: 2995-2997.
Martin K., Trouche D., Hagemeier C., Sorensen T. S., La Thangue N. B., and Kouzarides T. (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694.
Matsumura I., Ishikawa J., Nakajima K., Oritani K., Tomiyama Y., Miyagawa J.-I., Kato T., Miyazaki H., Matsuzawa Y., and Kanakura Y. (1997). Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21WAF1/Cip1 by STAT5. Mol. Cell. Biol. 17: 2933-2943.
McGregor J. M., Yu C. C., Dublin E. A., Barnes D. M., Levison D. A., and MacDonald D. M. (1993). p53 immunoreactivity in human malignant melanoma and dysplastic nevi. Br. J. Dermatol. 128: 606-611.
Medrano E. E., Im S., Yang F., and Abdel-Malek Z. A. (1995). Ultraviolet B light induces G1 arrest in human melanocytes by prolonged inhibition of retinoblastoma protein phosphorylation associated with long-term expression of the p21Waf-1/SDI-1/Cip-1 protein. Cancer Res. 55: 4047-4052.
Mellon I., Spivak G., and Hanawalt P. (1987). Selective removal of transcription-blocking DNA damage from the transcrobed strand of the mammalian DHFR gene. Cell 51: 241-249.
Merryman J. I. (1999). Effects of ultraviolet C radiation on cellular proliferation in p53-/- keratinocytes. J. Environ. Pathol. Toxicol. Oncol. 18: 1-9.
Michalowitz D., Halevy O., and Oren M. (1990). Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680.
Midgley C. A., Owens B., Briscoe C. V., Brynmor T., and Lane D. P. (1995). Coupling between gamma irradiation, p53 induction and the apoptotic response depends on cell type in vivo. J. Cell Sci. 108: 1843-1848.
Mitchell D. L., Jen J., and Cleaver J. E. (1989). The biology of the (6-4)photoproduct. Photochem. Photobiol. 49: 805-819.
Mitchell D.L., Jen J., and Cleaver J.E. (1992). Sequence specificity of cyclobutane pyrimidine dimers in DNA treated with solar (ultraviolet B) radiation. Nucleic Acids Res. 20: 225-229.
Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., and Reed J. C. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805.
Miyashita T., and Reed J. C. (1995). Tumor suppressor p53 is a transcriptional inducer of the human bax gene. Cell 80: 293-299.
Moll U., LaQuaglia M., Benard J., and Riou G. (1995). Wild-type p53 protein undergoes cytoplasmic sequesteration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92: 4407-4411.
Momand J., Zambetti G. P., Olson D. C., George D., and Levine A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
Momand J., and Zambetti G. P. (1997). Mdm-2: "big brother" of p53. J. Cell Biochem. 64: 343-352.
Montano X., Shamsher M., Whitehead P., Dawson K., and Newton J. (1994). Analysis of p53 in human cutaneus melanoma cell lines. Oncogene 9: 1455-1459.
Montes de Oca Luna R., Wagner D. S., and Lozano G. (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
Morris G. F., Bischoff J. R., and Mathews M. B. (1996). Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. USA 93: 895-899.
Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., and Deppert W. (1995). Negative feedback regulation of wild-type p53 biosynthesis. EMBO 14: 4442-4449.
Moustakas A., and Kardassis D. (1998). Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional inreactions between Sp1 and Smad family members. Proc. Natl. Acad. Sci. USA 95: 6733-6738.
Mummenbrauer T., Janus F., Muller B., Wiesmuller L., Deppert W., and Grosse F. (1996). p53 protein exhibits 3´-to-5´exonuclease activity. Cell 85: 1089-1099.
Nakazava H., English D., Randell P. L., Nakazava K., Martel N., Armstrong B. K., and Yamasaki H. (1994). UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc. Natl. Acad. Sci. USA 91: 360-364.
Nelson W. G., and Kastan M. B. (1994). DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14: 1815-1823.
Nicol C. J., Harrison M. L., laposa R. R., Gimelshtein I. L., and Wells P. G. (1995). A teratologic suppressor role for p53 in benzo-a-pyrene-treated transgenic p53-deficient mice. Nature Genet. 10: 181-187.
Niculescu A. B., Chen X., Smeets M., Hengst L., Prives C., and Reed S. I. (1998). Effects of p21Cip1/Waf1 at both the G1/S and G2/M cell cycle transitions: pRB is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18: 629-643.
Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., and Devilee P. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708.
Nikitin A. Y., and Lee W. H. (1996). Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice. Genes Dev. 10: 1870-1879.
Nishino H., Knoll A., Buettner V. L., Frisk C. S., Marura Y., Haavik J., and Sommer S. S. (1995). p53 wild-type and p53 nullizygous Big Blue transgenic mice have similar frquencies and patterns of observed mutation in liver, spleen, and brain. Oncogene 11: 263-270.
Noda A., Ning Y., Venable S. F., Pereira-Smith O. M., and Smith J. R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211: 90-98.
Ohta M., Nagai H., Shimizu M., Rasio D., Berd D., mastrangelo M., Singh A. D., Shileds J. A., Shields C. L., and Croce C. M. (1994). Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res. 54: 5269-5272.
Okamoto K., and Beach D. (1994). Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO 13: 4816-4822.
Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., and Vogelstein B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., and Vogelstein B. (1993). Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362: 857-860.
Olson D. C., Marechal V., Momand J., Chen J., Romocki C., and Levine A. R. (1993). Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8: 2353-2360.
Owen G. I., Richer J. K., Tung L., Takimoto G., and Horwitz K. B. (1998). Progesterone regulates transcription of the p21WAF1 Cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 273: 10696-10701.
Owen-Schaub L. B., Zhang W., Cusack J. C., Angelo L. S., Santee S. M., Fujiwara T., Roth J. A., Deisseroth A. B., Zhang W. W., and Kruzel E. (1995). Wild-type human p53 and temperature-sensitive mutant induce fas/APO-1 expression. Mol. Cell. Biol. 15: 3032-3040.
Pardee A. B. (1989). G1 events and regulation of cell proliferation. Science 246: 603-608.
Paulovich A. P., Toczyski D. P., and Hartwell L. H. (1997). When checkpoints fail. Cell 88: 315-321.
Pavletich N. P., Chambers K. A., and Pabo C. O. (1993). The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7: 2556-2564.
Perry M. E., Piette J., Zawadzki J. A., Harvey D., and Levine A. J. (1993). The mdm-2 oncogene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 90: 11623-11627.
Picksley S. M., Vojtesek B., Sparks A., and Lane D. P. (1994). Immunochemical analysis of the interaction of p53 with mdm2; fine mapping of the Mdm2 binding site on p53 using synthetic peptides. Oncogene 9: 2523-2529.
Pierce A. M., Fisher S. M., Conti C. J., and Johnson D. G. (1998). Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene 16: 1267-1276.
Pitkänen K., Haapajärvi T., and Laiho M. (1998). UVC-induction of p53 activation and accumulation is dependent on cell cycle and pathways involving protein synthesis and phosphorylation. Oncogene 16: 459-469.
Platz A., Hansson J., and Ringborg U. (1998). Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int. J. Cancer 78: 13-15.
Pollock P. M., Pearson J. V., and Hayward N. K. (1996). Complication of somatic mutation of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosom. Cancer 15: 77-88.
Poluha W., Schonhoff C. M., Harrington K. S., Lachyankar M. B., Crosbie N. E., Bulseco D. A., and Ross A. H. (1997). A novel, nerve growth factor-activated pathway involving nitric oxid, p53 and p21WAF1 regulates neuronal differentiation of PC12 cells. J. Biol. Chem. 272: 24002-24007.
Polyak K., Waldman T., He T. C., Kinzler K. W., and Vogelstein B. (1996). Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10: 1945-1952.
Pomerantz J., Schreiber-Agus N., Liegois N. J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H. W., Cordon-Cardo C., and DePinho R. A. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2´s inhibition of p53. Cell 92: 713-723.
Qian Y., Luckey C., Horton L., Esser M., and Templeten D. J. (1992). Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol. Cell. Biol. 12: 5363-5372.
Qin X.-Q., Livingston D. M., Kaelin W. G. J., and Adams P. (1994). Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 91: 10918-10922.
Quelle D. E., Zindy F., Ashmun R. A., and Sherr C. J. (1995a). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000.
Quelle D. E., Ashmun R. E., Hannon G. J., Rehberger P. A., Trono D., Richter K. H., Walker C., Beach D., Sherr C. J., and Serrano M. (1995b). Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11: 635-645.
Reed M., Woelker B., Wang P., Wang Y., Anderson M. E., and Tegtmeyer P. (1995). The C-terminal domain of p53 recognices DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA 92: 9455-9459.
Reismann P. T., Koga H., Takahashi R., Figlin R. A., Holmes E. C., Piantadosi S., Cordon-Cardo C., and Slamon D. J. (1993). Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 8: 1913-1919.
Reynisdottir I., Polyak K., Iavarone A., and Massague J. (1995). Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9: 1831-1845.
Robanus-Maandag E., Dekker M., van der Valk M., Carrozza M. L., jeanny J. C., Dannenberg J. H., Berns A., and te Riele H. (1998). p107 is a suppressor of retinoblastoma development in pRB-deficient mice. Genes Dev. 12: 1599-1609.
Roth J., Dobbelstein M., Freedman D. A., Shenk T., and Levine A. J. (1998). Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO 17: 554-564.
Ruggeri B., Zhang S. Y., Caamano J., DiRado M., Flynn S. D., and Klein-Szanto A. J. (1992). Human pancreatic carcinomas ans cell lines reveal frecuent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7: 1503-1511.
Sabbatini P., Lin J., Levine A. J., and White E. (1995a). Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 9: 2184-2192.
Sabbatini P., Chiou S. K., Rao L., and White E. (1995b). Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15: 1060-1070.
Sah V. P., Attardi L. D., Mulligan G. J., Williams B. O., Bronson R. T., and Jacks T. (1995). A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10: 175-180.
Saito M., Helin K., Valentine M. B., Griffith B. B., Willman C. L., Harlow E., and Look A. T. (1995). Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics 25: 130-138.
Sakaguchi K., Herrera J. E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C. W., and Appella E. (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12: 2831-2841.
Sandell L.L., and Zakian V.A. (1993). Loss of a yeast telomere: arrest, recovery, and chromosome lost. Cell 75: 729-739.
Sands A. T., Suraokar M. B., Sanchez A., Marth J. E., Donehower L. A., and Bradley A. (1995). p53 deficiency does not affect the accumulation of point mutations in a transgene target. Proc. Natl. Acad. Sci. USA 92: 8517-8521.
Saucedo L. J., Myers C. D., and Perry M. E. (1999). Multiple murine double minute gene 2 (MDM2) proteins are induced by ultraviolet light. J. Biol. Chem. 274: 8161-8168.
Savitsky K., A. B.-S., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D. A., Smith S., Uziel T., and Stef S. (1995). A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753.
Scheffner M., Huibregtse J. M., Viersta R. D., and Howley P. M. (1993). The HPV-16 E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
Schwartz D., Goldfinger N., and Rotter V. (1995). Expression of p53 protein in spermatogenesis is confined to the tetrapoid pachytene primary spermatocytes. Oncogene 8: 1487-1494.
Sedlacek Z., Kodet R., Seemanova E., Vodvarka P., Wilgenbus P., Mares J., Poustka A., and Goetz P. (1998). Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Br. J. Cancer 77: 1034-1039.
Selivanova G., Iotsova v., Okan I., Fritche M., Strom M., Groner B., Grafstrom R.C., and Wiman k.G. (1997). Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the C-terminal domain. Nature Med. 3: 632-638.
Selivanova G., Kawasaki T., Ryabchenko L., and Wiman K.G. (1998). Reactivation of mutant p53: a new strategy for cancer therapy. Sem. Cancer Biol. 8: 369-378.
Selivanova G., Ryabchenko L., Jansson E., Iotsova V., and Wiman K.G. (1999). Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell. Biol. 9: 3395-3402.
Serrano M., Hannon G. J., and Beach D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
Serrano M., Gomez-Lahoz E., DePinho R. A., Beach D., and Bar-Sagi D. (1995). Inhibition of Ras-induced proliferation and cellular transformation by p16INK4. Science 267: 249-252.
Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., and DePinho R. A. (1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
Serrano M., Lin A. W., McCurrach M. E., Beach D., and Lowe S. W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602.
Seto E., Usheva A., Zambetti G. P., Momand J., Horikoshi N., Weinmann R., Levine A. J., and Shenk T. (1992). Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89: 12028-12032.
Sewing A., Wiseman B., Lloyd A., and Land H. (1997). High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17: 5588-5597.
Shan B., and Lee W.-H. (1994). Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 14: 8166-8173.
Shaw P., Freeman J., Bovey R., and Iggo R. (1996). Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12: 921-930.
Shen Y., and Shenk T. (1994). Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc. Natl. Acad. Sci. USA 91: 8940-8944.
Sherr C. J. (1996). Cancer cell cycles. Science 274: 1672-1677.
Shieh S. Y., Ikeda M., Taya Y., and Prives C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
Shieh S. Y., Taya Y., and Prives C. (1999). DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO 18: 1815-1823.
Shivakumar C. V., Brown D. R., Deb S., and Deb S. P. (1995). Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol. Cell. Biol. 15: 6785-6793.
Shivji M. K. K., Grey S. J., Strausfeld U. P., Wood R. D., and Blow J. J. (1994). Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision repair. Curr. Biol. 4: 1062-1068.
Siegel J., Fritsche M., Mai S., Brandner G., and Hess R. D. (1995). Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection. Oncogene 11: 1363-1370.
Siliciano J. D., Canman C. E., Taya Y., Sakaguchi K., Appella E., and Kastan M. B. (1997). DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11: 3471-3481.
Slebos R. J. C., Lee M. H., Plunkett B. S., Kessis T. D., Williams B. O., Jacks T., Hedrick L., Kastan M. B., and Cho K. R. (1994). p53-dependent G1 arrest involves pRB related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA 91: 5320-5324.
Smith M. L., Chen I. T., Zhan Q., Bae I., Chen C. Y., Gilmer T. M., Kastan M. B., O´Conner P. M., and Fornace A. J. Jr. (1994). Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen. Science 266: 1376-1380.
Smith M. L., Chen I. T., Zhan Q., O'Connor P. M., and Fornace A. J. J. (1995). Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10: 1053-1059.
Smith M. L., Kontny H. U., Zhan Q., Sreenath A., O´Connor P. M., and Fornace Jr A. J. (1996). Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Oncogene 13: 2255-2263.
Somasundaram K., Zhang H., Zeng Y.-X., Houvras Y., Peng Y., Zhang H., Wu G. S., Licht J. D., Weber B. L., and El-Deiry W. S. (1997). Arrest of the cell cycle by tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CIp1. Nature 389: 187-190.
de Stanchina E., McCurrach M. E., Zindy F., Shieh S. Y., ferbeyre G., samuelson A. V., Prives C., Roussel M. F., Sherr C. J., and Lowe S. W. (1998). E1A signaling to p53 involves the 19ARF tumor suppressor. Genes Dev. 12: 2435-2443.
Steegenga W. T., van der Eb A. J., and Jochemsen A. G. (1996). How phosphorylation regulates the activity of p53. J. Mol. Biol. 263: 103-113.
Stefanini M., Lagomarsini P., Giliani S., Nardo T., Botta E., Peserico A., Kleijer W. J., Lehmann A. R., and A. S. (1993). Genetic heterogeneity of the excision repair defect associated with trichothiodystrophy. Carcinogenesis 14: 1101-1105.
Stewart N., Hicks G. G., Parakevas F., and Mowat M. (1995). Evidence for a second cell cycle clock block at G2/M by p53. Oncogene 10: 109-115.
Stone S., Jiang P., Dayananth P., tavtigian S. V., Katcher H., Parry D., Peters G., and Kamb A. (1995). Complex structure and regulation of the p16(MTS1) locus. Cancer Res. 55: 2988-2994.
Stone-Wolff D. S., and Rossman T. G. (1982). Demonstration of recovery from the potentially mutagenic effects of ultra-violet light by replication inhibited Chinese hamster V79 cells. Mutat. Res. 95: 493-503.
Stott F. J., Bates S., James M. C., McConnell B. B., Starborg M., Brookes S., Palmero I., Rayn K., Hara E., Vousden K. H., and Peters G. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO 17: 5001-5014.
Takenaka I., Morin F., Seizinger B. R., and Kley N. (1995). Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem. 270: 5405-5411.
Taylor J.-S., Garret D. S., and Cohrs M. P. (1988). Solution-state structure of the Dewar pyrimidinone photoproduct of thymidylyl-(3´-5´)-thymidine. Biochemistry 27: 7206-7215.
Taylor J.-S., Garret D. S., Brockie I. R., Svoboda D. L., and Telser J. (1990). H NMR assignement and melting temperature study of cis-syn and tran-syn thymine dimer containing duplexes of d(CGTATTATGC).d(GCATAATACG). Biochemistry 29: 8858-8866.
Thut C., Chen J. L., Klemm R., and Tjian R. (1995). p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267: 100-104.
Tibbets R. S., Brumbaugh K. M., Williams J. M., Sarkaria J. N., Cliby W. A., Shieh S. Y., Taya Y., Prives C., and Abraham R. T. (1999). A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13: 152-157.
Timchenko N. A., Wilde M., Nakanishi M., Smith J. R., and Darlington G. J. (1996). CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev. 10: 804-815.
Tornaletti S., Rozek D., and Pfeifer G.P. (1993). The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene 8: 2051-2057.
Tsao H., Benoit E., Sober A. J., Thiele C., and Haluska F. G. (1998). Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res. 58: 109-113.
Tyrrell R. M. (1991). UVA (320-380 nm) radiation as an oxidative stress. Oxidative stress: oxidants and antioxidants 57-85.
T´Ang A., Varley J. M., Chakraborty S., Murphree A. L., and Fung Y. K. (1988). Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242: 263-266.
Unger T., Juven-Gershon T., Moallem E., Berger M., Vogt Sionov R., Lozano G., Oren M., and Haupt Y. (1999). Critical role for ser20 of human p53 in the negative regulation of p53 by mdm2. EMBO 18: 1805-1814.
van Hoffen A., Natarajan A. T., Mayne L. V., van Zeeland A. A., Mullenders L. H., and Venema J. (1993). Deficient repair of the transcribed strand of active genes in Cockaynes´s syndrome cells. Nucleic Acids Res. 21: 5890-5895.
Van Meir E. G., Polverini P. J., Chazin V. R., Su Huang H.-J., de Tribolet N., and Cavanee W. K. (1994). Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet. 8: 171-176.
Varley J. M., McGown G., Thornecroft M., Santibanez-Koref M. F., Kelsey A. M., Tricker K. J., Evans D. G., and Birch J. M. (1997). Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 57: 3245-3252.
Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., and Debussche L. (1998). The requirement of the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO 17: 4668-4679.
Waga S., Hannon G. J., Beach D., and Stillman B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578.
Wagner A. J., Kokontis J. M., and Hay N. (1994). Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8: 2817-2830.
Waldman T., Kinzler K. W., and Vogelstein B. (1995). p21 is necessary for the p53-mediated G1-arrest in human cancer cells. Cancer Res. 55: 5187-5190.
Walker G. J., Hussussian C. J., Flores J. F., Glendening J. M., Haluska F. G., Dracopoli N. C., Hayward N. K., and Fountain J. W. (1995). Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum. Mol. Genet. 4: 1845-1852.
Walker K. K., and Levine A. J. (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93: 15335-15340.
Wang X. W., Yeh H., Schaeffer L., Roy R., Moncollin V., Egly J. M., Wang Z., Freidberg E. C., Evans M. K., and Taffe B. G. (1995). p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 10: 188-195.
Wang X. W., Vermeulen W., Coursen J. D., Gibson M., Lupold S. E., Forrester K., Xu G., Elmore L., Yeh H., Hoeijmakres J. H., and Harris C. C. (1996). The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 10: 1219-1232.
Waterman M. J., Stavridi E. S., Waterman J. L. F., and Halazonetis T. D. (1998). ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genet. 19: 175-178.
Weichselbaum R. R., Beckett M., and Diamond A. (1988). Some retinoblastomas, osteosarcomas, and softtissue sarcomas may share a common etiology. Proc. Natl. Acad. Sci. USA 85: 2106-2109.
Weinberg R. A. (1995). The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
Weintraub S. J., Prater C. A., and Dean D. C. (1992). Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358: 259-261.
Weiss J., Heine M., Arden K. C., Korner B., Pilch H., Herbst R. A., and Jung E. G. (1995). Mutation and expression of TP53 in malignant melanomas. Cancer Res. 139: 137-154.
Welch P. J., and Wang J. Y. J. (1995). Disruption of retinoblatoma protein function by co-expression of its C pocket fragment. Genes Dev. 9: 31-46.
White A. E., Livanos E. M., and Tlsty T. D. (1994). Differential disruption of genomic integrity and cell cycle regulation in normal fibroblasts by the HPV oncoproteins. Genes Dev. 8: 666-667.
White R. J., Trouche D., Martin K., Jackson S. P., and Kouzarides T. (1996). Repression of RNA polymerase III by the retinoblastoma protein. Nature 382: 88-90.
Whyte P., Buchkowich K., Horowitz J. M., Friend S. H., Raybuck M., Weinberg R. A., and Harlow E. (1988). Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124-129.
Wilkie A.O., Lamb J., Harris P.C., Finney R.D., and Higgs D.R. (1990). A truncated human chromosome 16 associated with alpha thalassemia in stabilized by addition of telomeric repeat (TTAGGG)n. Nature 346: 868-871.
Wolf D., and Rotter V. (1985). Major deletions in the gene encoding the p53 tumor antigen cause lack of expression in HL-60 cells. Proc. Natl. Acad. Sci. USA 82: 790-794.
Woo R. A., McLure K. G., Lees-Miller S. P., Rancourt D. E., and Lee P. W. (1998). DNA-dependent protein kinase acts upstrem of p53 in response to DNA damage. Nature 394: 700-704.
Woods D., Parry D., Cherwinski H., Bosch E., Lees E., and McMahon M. (1997). Raf-induced proliferation or cellãcycle arrest is determined by the level of Raf-activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17: 5598-5611.
Wu G. S., Burns T. F., McDonald E. R. 3., Jiang W., Meng R., Krantz I. D., Kao G., Gan D. D., Zhou J. Y., Muchel R., hamilton S. R., Spinner N. B., Markowitz S., Wu G., and El-Deiry W. S. (1997). Killer/DR5 is a DNA damage inducible p53-regulated death receptor gene. Nature Genet. 17: 141-143.
Wu L., Bayle J. H., Elenbaas B., Pavletich N. P., and Levine A. J. (1995). Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol. 15: 497-504.
Wu L., and Levine A. J. (1997). Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 3: 441-451.
Wu R. C., and Schonthal A. H. (1997). Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J. Biol. Chem. 272: 29091-29098.
Wu X., Bayle J. H., Olson D., and Levine A. J. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126-1132.
Wu X., and Levine A. J. (1994). p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91: 3602-3606.
Xiao Z. X., Chen J., Levine A. J., Modjtahedi N., Xing J., Sellers W. R., and Livingston D. M. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., and Dyson N. (1996). Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85: 537-548.
Yamasaki L., Bronson R., Williams B. O., Dyson N. J., Harlow E., and Jacks T. (1998). Loss of E2F-1 reduces tumorigenesis and extends life-span of Rb(+/-) mice. Nature Genet. 18: 360-364.
Yan G.-Z., and Ziff E. B. (1997). Nerve growth factor induces transcription of the p21WAF1/CIP1 and Cyclin D1 genes in PC12 cells by activating the Sp1 transcription factor. J. Neurosci. 17: 6122-6132.
Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., caput D., and McKeon F. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2: 305-316.
Yen A., and Sturgill R. (1998). Hypophosphorylation of the RB protein in S and G2 as well as G1 during growth arrest. Exp. Cell Res. 241: 324-331.
Yokota J., Akiyama T., Fung Y. K., Benedict W. F., Namba Y., Hanaoka M., Wada M., Terasaki T., Shimosato Y., and Sugimura T. (1988). Altered expression of the retinoblastoma (RB) gene in small-cell caricinoma of the lung. Oncogene 3: 471-475.
Yonish-Rouach E., Deguin V., Zaitchouk T., Breugnot C., Mishal Z., Jenkins J., and May E. (1995). Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 11: 2197-2205.
Zauberman A., Lupo A., and Oren M. (1995). Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene 10: 2361-2366.
Zerp S. F., van Elsas A., Peltenburg L. T., and Schrier P. I. (1999). p53 mutations in human cutaneus melanoma correlates with sun exposure but are not always involved in melanomagenesis. Br. J. Cancer 79: 921-926.
Zhan Q., Carrier F., and Fornace A. J. J. (1993). Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol. 13: 4242-4250.
Zhan Q., Bae I., Kastan M. B., and Fornace A. J. Jr. (1994). The p53-dependent gamma-ray response of GADD45. Cancer Res. 54: 2755-2760.
Zhan Q., Fan S., Smith M.L., Bae I., Yu K., Alamo I. Jr., O´Connor P.M., and Fornace A.J. Jr. (1996).
Abrogation of p53 function affects gadd gene responses to DNA base damaging agents and starvation. DNA and Cell Biol. 15: 805-815.
Zhang H. S., Postigo A. A., and Dean D. C. (1999). Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 97: 53-61.
Zhang Y., Xiong Y., and Yarbrough W. G. (1998). ARF protects MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tunor suppressor. Cell 92: 725-734.
Zhang Y., and Xiong Y. (1999). Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Molecular Cell 3: 579-591.
Zhu J., Jiang J., Zhou W., Zhu K., and Chen X. (1999). Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impired apoptotic activity. Oncogene 18: 2149-2155.
Ziegler A., Leffell D. J., Kunala S., Sharma H. W., Gailani M., Simon J. A., Halperin A. J., Baden H. P., Shapiro P. E., Bale A. E., and Brash D. E. (1993). Mutation hotspot due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc. Natl. Acad. Sci. USA 90: 4216-4220.
Ziegler A., Jonason A. S., Leffell D. J., Simon J. A., Sharma H. W., Kimmelman J., Remington L., Jacks T., and Brash D. E. (1994). Sunburn and p53 in the onset of skin cancer. Nature 372: 773-776.
Zindy F., Eichen C. M., Randle D. H., Kamijo T., Cleveland J. L., Sherr C. J., and Roussel M. F. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424-2433.
Zuo L., Weger J., Yang Q., Goldstein A. M., Tucker M. A., Walker G. J., Hayward N., and Dracopoli N. C. (1996). Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 12: 97-99.